Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline
Acadia Pharmaceuticals (ACAD) outlined at Canaccord Genuity’s Growth Conference its commercial progress and pipeline. Management said NUPLAZID is at a $700 million annualized sales run rate, with 20% YoY growth in new-to-brand prescriptions, and DAYBUE STIX reached 60% of June prescriptions. Acadia has about $1 billion cash and expects Phase II/III remlifanserin Alzheimer’s disease psychosis data in Sep-Oct 2024.
How this was made
The 30-second read
Why it matters
Traders may use the quantified product momentum and the stated remlifanserin readout window to frame expectations, but the article does not introduce a new trial result, approval, or filing.
Market read
Company-specific commercial traction and a stated clinical readout window can influence positioning, but this is not a fresh regulatory or trial outcome.
What to watch
Europe approval timing for DAYBUE and any label differences could affect the magnitude and pace of ex-US growth, while competitive dynamics in Parkinson’s disease psychosis could pressure category awareness gains.
Background
The piece summarizes Acadia’s management presentation at Canaccord Genuity’s Growth Conference, focusing on commercial performance and pipeline catalysts.
Ticker impact
Acadia used the Canaccord Genuity conference to reiterate NUPLAZID at a $700M annualized run rate and DAYBUE STIX uptake, plus a remlifanserin readout window.
Bias modestly positive into the September to October 2024 remlifanserin window, with volatility around any subsequent trial/regulatory updates.
The article provides specific commercial metrics and a defined clinical readout timeframe, but it is still a conference narrative rather than a new regulatory filing or trial result.
Market effects
Highlights continued commercial traction in rare neuropsychiatric drugs and keeps attention on Alzheimer’s disease psychosis pipeline competition.
No direct regional market impact beyond potential Europe launch timing for DAYBUE.
Limited global relevance; mostly company-specific commercial and pipeline updates.
Counterpoint
Commercial metrics may not offset the binary risk of late-stage remlifanserin data and regulatory outcomes, so the stock could re-rate lower if trial signals disappoint.
Key entities
- companyAcadia Pharmaceuticals
Subject of the conference update, covering NUPLAZID, DAYBUE (including STIX), and remlifanserin clinical timing.
- productNUPLAZID
Parkinson’s disease psychosis drug cited at a $700M annualized sales run rate and 20% YoY new-to-brand growth.
- productDAYBUE
Rett syndrome drug, with STIX formulation gaining share and persistency metrics cited.
- pipeline_assetremlifanserin
Phase II/III asset in Alzheimer’s disease psychosis and Lewy body dementia, with a September or October 2024 readout expectation stated.
